Samsung Bioepis expands in China with second partner in two months
Samsung Bioepis announces licensing agreement with C-Bridge to bring ‘third-wave’ biosimilars to the Chinese market.
Archives for February 12, 2019
AbbVie enters $90m agreement to develop multiple myeloma immunotherapy
AbbVie and Teneobio enter an agreement to develop and commercialize an immunotherapeutic for the treatment of multiple myeloma using the latter’s proprietary anti-CD3 platform.